» Articles » PMID: 26217586

Range Verification Methods in Particle Therapy: Underlying Physics and Monte Carlo Modeling

Overview
Journal Front Oncol
Specialty Oncology
Date 2015 Jul 29
PMID 26217586
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Hadron therapy allows for highly conformal dose distributions and better sparing of organs-at-risk, thanks to the characteristic dose deposition as function of depth. However, the quality of hadron therapy treatments is closely connected with the ability to predict and achieve a given beam range in the patient. Currently, uncertainties in particle range lead to the employment of safety margins, at the expense of treatment quality. Much research in particle therapy is therefore aimed at developing methods to verify the particle range in patients. Non-invasive in vivo monitoring of the particle range can be performed by detecting secondary radiation, emitted from the patient as a result of nuclear interactions of charged hadrons with tissue, including β (+) emitters, prompt photons, and charged fragments. The correctness of the dose delivery can be verified by comparing measured and pre-calculated distributions of the secondary particles. The reliability of Monte Carlo (MC) predictions is a key issue. Correctly modeling the production of secondaries is a non-trivial task, because it involves nuclear physics interactions at energies, where no rigorous theories exist to describe them. The goal of this review is to provide a comprehensive overview of various aspects in modeling the physics processes for range verification with secondary particles produced in proton, carbon, and heavier ion irradiation. We discuss electromagnetic and nuclear interactions of charged hadrons in matter, which is followed by a summary of some widely used MC codes in hadron therapy. Then, we describe selected examples of how these codes have been validated and used in three range verification techniques: PET, prompt gamma, and charged particle detection. We include research studies and clinically applied methods. For each of the techniques, we point out advantages and disadvantages, as well as clinical challenges still to be addressed, focusing on MC simulation aspects.

Citing Articles

Size-Sorted Superheated Nanodroplets for Dosimetry and Range Verification of Carbon-Ion Radiotherapy.

Toumia Y, Pullia M, Domenici F, Mereghetti A, Savazzi S, Ferrarini M Nanomaterials (Basel). 2024; 14(20).

PMID: 39452979 PMC: 11509999. DOI: 10.3390/nano14201643.


A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy.

Jang J, Kim K, Chen M, Akimoto T, Wang M, Kim M Cancer Med. 2024; 13(3):e7023.

PMID: 38396380 PMC: 10891363. DOI: 10.1002/cam4.7023.


Quasi-real-time range monitoring by in-beam PET: a case for O.

Purushothaman S, Kostyleva D, Dendooven P, Haettner E, Geissel H, Schuy C Sci Rep. 2023; 13(1):18788.

PMID: 37914762 PMC: 10620432. DOI: 10.1038/s41598-023-45122-2.


Emerging technologies for cancer therapy using accelerated particles.

Graeff C, Volz L, Durante M Prog Part Nucl Phys. 2023; 131:104046.

PMID: 37207092 PMC: 7614547. DOI: 10.1016/j.ppnp.2023.104046.


A high sensitivity Cherenkov detector for prompt gamma timing and time imaging.

Jacquet M, Ansari S, Gallin-Martel M, Andre A, Boursier Y, Dupont M Sci Rep. 2023; 13(1):3609.

PMID: 36869125 PMC: 9984540. DOI: 10.1038/s41598-023-30712-x.


References
1.
Jan S, Benoit D, Becheva E, Carlier T, Cassol F, Descourt P . GATE V6: a major enhancement of the GATE simulation platform enabling modelling of CT and radiotherapy. Phys Med Biol. 2011; 56(4):881-901. DOI: 10.1088/0031-9155/56/4/001. View

2.
Peterson S, Robertson D, Polf J . Optimizing a three-stage Compton camera for measuring prompt gamma rays emitted during proton radiotherapy. Phys Med Biol. 2010; 55(22):6841-56. PMC: 3068559. DOI: 10.1088/0031-9155/55/22/015. View

3.
Tashima H, Yamaya T, Yoshida E, Kinouchi S, Watanabe M, Tanaka E . A single-ring OpenPET enabling PET imaging during radiotherapy. Phys Med Biol. 2012; 57(14):4705-18. DOI: 10.1088/0031-9155/57/14/4705. View

4.
Parodi K, Ferrari A, Sommerer F, Paganetti H . Clinical CT-based calculations of dose and positron emitter distributions in proton therapy using the FLUKA Monte Carlo code. Phys Med Biol. 2007; 52(12):3369-87. PMC: 2292644. DOI: 10.1088/0031-9155/52/12/004. View

5.
Knopf A, Nill S, Yohannes I, Graeff C, Dowdell S, Kurz C . Challenges of radiotherapy: report on the 4D treatment planning workshop 2013. Phys Med. 2014; 30(7):809-15. DOI: 10.1016/j.ejmp.2014.07.341. View